Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
27 |
Employees |
- |
Revenues (TTM) (Millions $) |
13 |
Net Income (TTM) (Millions $) |
-20 |
Cash Flow (TTM) (Millions $) |
-17 |
Capital Exp. (TTM) (Millions $) |
0 |
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc is a biopharmaceutical company based in the United States. They focus on the development of cancer therapeutics, specifically targeting the needs of pediatric patients. The company's lead product candidate is known as PEDMARK, which is being developed to prevent ototoxicity, or hearing loss, caused by certain chemotherapy agents. Fennec Pharmaceuticals Inc aims to address the significant unmet medical needs in pediatric oncology and improve outcomes for these patients.
Company Address: PO Box 13628, 68 TW Alexander Drive Research Triangle Park 27709 NC
Company Phone Number: 636-4530 Stock Exchange / Ticker: NASDAQ FENCF
FENCF is expected to report next financial results on March 28, 2024. |
|
|